Histopathological differential diagnosis of primary liver tumors

Česká verzia

Authors: E. Honsová
Authors place of work: Pracoviště klinické a transplantační patologie, Transplantcentrum IKEM Praha přednostka: Doc. MUDr. E. Honsová, Ph. D.
Published in the journal: Rozhl. Chir., 2014, roč. 93, č. 3, s. 170-175.
Category: Various Specialization

Práce byla podpořena: MZ ČR – RVO („Institut klinické a experimentální medicíny – IKEM, IČ 00023001“)
Práce je určena k postgraduálnímu vzdělávání lékařů.

Summary

The most common primary hepatic malignancy is hepatocellular carcinoma, which constitutes 80–85% of all malignant epithelial neoplasms originating in the liver. The second most common primary hepatic malignancy is cholangiocellular carcinoma. In recent years, remarkable progress has been made in elucidating the molecular pathology of hepatic tumors. Advances in our understanding of molecular subtypes have led to a creation of a new classification system of hepatocellular adenomas, with important genotype-phenotype correlations and easy application to routine diagnostic practice. In the field of early hepatic neoplasia, a consensus on the definition of dysplastic nodules and early hepatocellular carcinoma has been reached. Immunohistochemical detection of glypican-3 and stromal invasion are used for the differential diagnosis. A lot of problems still exist in the category of mixed hepatocellular and cholangiocellular carcinoma. Although this category is recognized in the WHO classification, confusing terminology has been generated to describe tumors with morphological features of both HCC and CC. We further specify problems and pitfalls of the differential histopathological diagnosis of liver malignant tumors.

Key words:
hepatocellular carcinoma – cholangiocellular carcinoma – liver adenoma

Zdroje

1. International Consensus group for hepatocellular neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658–664.

2. Pracovní skupina HCC 2011. Doporučený postup pro léčbu a diagnostiku hepatocelulárního karcinomu. Gastroent Hepatol 2012;66:83–92.

3. Honsová E, Lodererová A, Franková S, et al. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma. Cas Lek Cesk 2011;150:37–40.

4. Filmus J. Glypican in growth control and cancer. Glycobiology 2001;11:19–23.

5. Takai H, Kato A, Ishiguro T, at al. Optimization of tissue processing for immunohitochemistry for the detection of human glypican-3. Acta Histochem 2010;112:240–250.

6. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican-3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol 2008;130:224–230.

7. Honsová E. Histopatologická diagnóza hepatocelulárního karcinomu. Gastroent Hepatol 2012;66:93–98.

8. Walther Z, Jain D. Molecular Pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int 2011;7:1–15.

9. Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epitheloid hemangioendothelioma. A comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006;107:2108–2121.